{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:11:10Z","timestamp":1792001470488,"version":"4.4.0"},"reference-count":36,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,28]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Tusamitamab ravtansine is an antibody\u2013drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and delivers a cytotoxic maytansinoid payload. In a phase I dose-escalation study, the maximum tolerated dose (MTD) was 100 mg\/m2 every 2 weeks (Q2W). Here we report results for two alternative schedules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Adults ages \u226518 years (range, 34\u201373) with locally advanced\/metastatic solid tumors (N = 43; colon\/rectum, 29; stomach, 7; pancreas, 4; other, 3) expressing\/likely to express CEACAM5 received intravenous tusamitamab ravtansine 120\u2013170 mg\/m2 [loading dose (LD)], then 100 mg\/m2 Q2W (Q2W-LD, n = 28), or 120\u2013190 mg\/m2 fixed dose [every 3 weeks (Q3W), n = 15]. The primary endpoint was dose-limiting toxicities (DLTs) during cycles 1\u20132 (Q2W-LD) and cycle 1 (Q3W).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Reversible DLTs were observed in 2 of 9 patients (grade 2 keratopathy; grade 2 keratitis) with 170 mg\/m2 in Q2W-LD and in 2 of 3 patients (grade 2 keratopathy; grade 3 transaminase elevation) with 190 mg\/m2 in Q3W. Nineteen (67.9%) patients in Q2W-LD and 13 (86.7%) patients in Q3W experienced treatment-related adverse events (AE); 3 of 43 patients discontinued treatment because of AEs. The most common AEs were asthenia, gastrointestinal complaints, keratopathy, keratitis, and peripheral sensory neuropathy. In this small, heavily pretreated population, no confirmed responses were observed; however, stable disease occurred in 35.7% of patients in Q2W-LD and 40.0% of patients in Q3W.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Tusamitamab ravtansine had a favorable safety profile with both alternative administration schedules; MTDs were 170 mg\/m2 (LD) followed by 100 mg\/m2 Q2W, and 170 mg\/m2 Q3W as a fixed dose. (NCT02187848).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The collective results of this phase I dose-escalation study will inform further studies of tusamitamab ravtansine in patients with solid tumors with CEACAM5 expression, including patients with non\u2013small cell lung cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0284","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T09:44:05Z","timestamp":1691055845000},"page":"1662-1671","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":true,"given":"Josep","family":"Tabernero","sequence":"first","affiliation":[{"name":"1Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quir\u00f3n, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-2999","authenticated-orcid":true,"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre\u2014University Health Network, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6000-4597","authenticated-orcid":true,"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-343X","authenticated-orcid":true,"given":"Maria","family":"Vieito","sequence":"additional","affiliation":[{"name":"4Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-1263","authenticated-orcid":true,"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7381-8657","authenticated-orcid":true,"given":"Nathalie","family":"Fagniez","sequence":"additional","affiliation":[{"name":"6Pharmacokinetics, Dynamics and Metabolism, Sanofi, Chilly-Mazarin, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1376-8872","authenticated-orcid":true,"given":"Mustapha","family":"Chadjaa","sequence":"additional","affiliation":[{"name":"7Clinical Development, Sanofi, Vitry-sur-Seine, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7120-5756","authenticated-orcid":true,"given":"Christine","family":"Soufflet","sequence":"additional","affiliation":[{"name":"7Clinical Development, Sanofi, Vitry-sur-Seine, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6665-6032","authenticated-orcid":true,"given":"Nina","family":"Masson","sequence":"additional","affiliation":[{"name":"8IT&M STATS on behalf of Sanofi, Neuilly-sur-Seine, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6866-6787","authenticated-orcid":true,"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[{"name":"9Department of Drug Development (DITEP), Gustave Roussy, Villejuif Cedex, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"2023082814074717100_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/scbi.1998.0119","article-title":"The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues","volume":"9","author":"Hammarstr\u00f6m","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"2023082814074717100_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2021.12.002","article-title":"Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer","volume":"163","author":"Desai","year":"2022","journal-title":"Lung Cancer"},{"key":"2023082814074717100_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2407-7-2","article-title":"Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers","volume":"7","author":"Blumenthal","year":"2007","journal-title":"BMC Cancer"},{"key":"2023082814074717100_bib4","doi-asserted-by":"crossref","first-page":"300060520959478","DOI":"10.1177\/0300060520959478","article-title":"CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration","volume":"48","author":"Zhang","year":"2020","journal-title":"J Int Med Res"},{"key":"2023082814074717100_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1021\/acs.jproteome.5b00819","article-title":"Quantitative secretomic analysis identifies extracellular protein factors that modulate the metastatic phenotype of non-small cell lung cancer","volume":"15","author":"Hu","year":"2016","journal-title":"J Proteome Res"},{"key":"2023082814074717100_bib6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1369\/0022155415609098","article-title":"Identification of CEACAM5 as a biomarker for prewarning and prognosis in gastric cancer","volume":"63","author":"Zhou","year":"2015","journal-title":"J Histochem Cytochem"},{"key":"2023082814074717100_bib7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/ijms22020925","article-title":"Assessment of the efficacy and clinical utility of different circulating tumor cell (CTC) detection assays in patients with chemotherapy-naive advanced or metastatic non-small cell lung cancer (NSCLC)","volume":"22","author":"Papadaki","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023082814074717100_bib8","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1002\/cam4.1814","article-title":"The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer\u2014a retrospective cohort study","volume":"7","author":"Tong","year":"2018","journal-title":"Cancer Med"},{"key":"2023082814074717100_bib9","article-title":"A novel anti-CEACAM5 maytansinoid-antibody-drug conjugate for the treatment of colorectal, lung and gastric tumors [abstract]","author":"Decary"},{"key":"2023082814074717100_bib10","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023082814074717100_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10928-021-09799-0","article-title":"Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate","volume":"49","author":"Pouzin","year":"2022","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2023082814074717100_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/bc900315y","article-title":"Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates","volume":"21","author":"Erickson","year":"2010","journal-title":"Bioconjug Chem"},{"key":"2023082814074717100_bib13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann Oncol"},{"key":"2023082814074717100_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9505","article-title":"Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)","volume":"38","author":"Gazzah","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023082814074717100_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9039","article-title":"Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non\u2013small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)","author":"Ricordel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023082814074717100_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"2023082814074717100_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","article-title":"Drug-induced corneal epithelial changes","volume":"62","author":"Raizman","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"2023082814074717100_bib18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"2023082814074717100_bib19","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"key":"2023082814074717100_bib20","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","article-title":"Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023082814074717100_bib21","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Invest New Drugs"},{"key":"2023082814074717100_bib22","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-18-0481","article-title":"Phase I trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas","volume":"24","author":"Thompson","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023082814074717100_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.3062","article-title":"A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors","volume":"25","author":"Mita","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023082814074717100_bib24","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00280-017-3451-1","article-title":"Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study","volume":"80","author":"van den Bent","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023082814074717100_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"2023082814074717100_bib26","doi-asserted-by":"crossref","first-page":"678634","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front Oncol"},{"key":"2023082814074717100_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol"},{"key":"2023082814074717100_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023082814074717100_bib29","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2023082814074717100_bib30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"2023082814074717100_bib31","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","article-title":"Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial","volume":"105","author":"Popat","year":"2020","journal-title":"Haematologica"},{"key":"2023082814074717100_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"2023082814074717100_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS9625","article-title":"Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy","volume":"38","author":"Johnson","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023082814074717100_bib34","doi-asserted-by":"crossref","first-page":"S1034","DOI":"10.1016\/j.annonc.2021.08.1965","article-title":"Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy","volume":"32","author":"Cho","year":"2021","journal-title":"Ann Oncol"},{"key":"2023082814074717100_bib35","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.annonc.2022.02.084","article-title":"Open-label, phase 2 study of tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and with pembrolizumab + platinum-based chemotherapy +\/\u2212 pemetrexed in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05)","volume":"33","author":"Paz-Ares","year":"2022","journal-title":"Ann Oncol"},{"key":"2023082814074717100_bib36","doi-asserted-by":"crossref","first-page":"S1124","DOI":"10.1016\/j.annonc.2022.07.1379","article-title":"CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA\/GEJA)","volume":"33","author":"Esposito","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0284\/3353685\/crc-23-0284.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/8\/1662\/3360375\/crc-23-0284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/8\/1662\/3360375\/crc-23-0284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T12:47:17Z","timestamp":1729860437000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/8\/1662\/728664\/Tusamitamab-Ravtansine-in-Patients-with-Advanced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,28]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0284","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24043017.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043014.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24042999","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834542.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24042999.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043011.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043029","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834542","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043005","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043017","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834560.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834554","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043014","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043026","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043002","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834557","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043020.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834545","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043023.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043011","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834551.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834554.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834560","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043002.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043005.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043008.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043023","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834548","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834557.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834548.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043020","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043026.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043029.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834545.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043008","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834551","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.24043020.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834557","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043026","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043023.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043026.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834545","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043029.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043014","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043002","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834548","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043029","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6773851.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043017","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043005","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834560","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043002.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043008.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043005.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043011.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24042999.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043014.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043017.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6773851.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834551","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834545.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834542.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043008","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043020","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834557.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834554.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834548.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24042999","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6773851","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834551.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834554","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834542","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23834560.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043023","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24043011","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}